Summarized by Masters of Longevity from Nature - Main.
In vivo CAR-T developments in China: a news feature that examines why researchers there are rapidly moving next‑generation cell therapies into clinical testing and what that means for global research opportunities.
Key Takeaways
- China accounts for about 82% of the 140 global in vivo CAR-T therapies being tested in animals and people.
- Investigator-initiated trials in China let researchers test cell and gene therapies quickly without central regulator oversight.
- Early human results from China show symptom improvements in multiple autoimmune and blood-cancer cases with manageable short-term safety.
